NEW YORK (GenomeWeb News) – Accelerate Diagnostics said today it raised $45 million from a rights offering commenced last month.

About $25.5 million was raised from shareholders who subscribed for more than 1.5 million shares of the Tucson, Ariz.-based firm's common stock. It said that approximately 58 percent of the shares were subscribed for by Accelerate's directors, and added that 57 percent of stockholders exercised their subscription privileges.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.